CH646700A5 - Composes de benzodiazepine et produits pharmaceutiques les contenant. - Google Patents
Composes de benzodiazepine et produits pharmaceutiques les contenant. Download PDFInfo
- Publication number
- CH646700A5 CH646700A5 CH763980A CH763980A CH646700A5 CH 646700 A5 CH646700 A5 CH 646700A5 CH 763980 A CH763980 A CH 763980A CH 763980 A CH763980 A CH 763980A CH 646700 A5 CH646700 A5 CH 646700A5
- Authority
- CH
- Switzerland
- Prior art keywords
- group
- hydrogen atom
- formula
- alkyl
- compound
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title description 2
- 229940127557 pharmaceutical product Drugs 0.000 title description 2
- 150000001557 benzodiazepines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 109
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 54
- -1 C 2 -C 4 acyl group Chemical group 0.000 claims description 41
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 22
- 238000006243 chemical reaction Methods 0.000 claims description 22
- 239000002253 acid Substances 0.000 claims description 20
- 125000005843 halogen group Chemical group 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 150000001412 amines Chemical class 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000003277 amino group Chemical group 0.000 claims description 14
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 14
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 13
- 125000001188 haloalkyl group Chemical group 0.000 claims description 11
- 238000007363 ring formation reaction Methods 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000002252 acyl group Chemical group 0.000 claims description 7
- 230000003647 oxidation Effects 0.000 claims description 7
- 238000007254 oxidation reaction Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims description 3
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 92
- 230000008018 melting Effects 0.000 description 56
- 238000002844 melting Methods 0.000 description 56
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 54
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 51
- 239000000203 mixture Substances 0.000 description 48
- 239000000243 solution Substances 0.000 description 28
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 24
- CFEMJBULLJKFOS-UHFFFAOYSA-N pyrazolo[3,4-b][1,5]benzodiazepine Chemical compound N1=C2C=CC=CC2=NC=C2C=NN=C21 CFEMJBULLJKFOS-UHFFFAOYSA-N 0.000 description 23
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 8
- 150000001408 amides Chemical class 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- ZVAPWJGRRUHKGP-UHFFFAOYSA-N 1h-1,5-benzodiazepine Chemical compound N1C=CC=NC2=CC=CC=C12 ZVAPWJGRRUHKGP-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 125000003396 thiol group Chemical group [H]S* 0.000 description 6
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 229910003074 TiCl4 Inorganic materials 0.000 description 4
- 150000001409 amidines Chemical class 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 2
- XNJAYQHWXYJBBD-UHFFFAOYSA-N 1,4-difluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(F)=CC=C1F XNJAYQHWXYJBBD-UHFFFAOYSA-N 0.000 description 2
- WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 2
- JLAAUZHMAFBKAW-UHFFFAOYSA-N 1-n-(1-methylpyrazol-3-yl)-4-(trifluoromethyl)benzene-1,2-diamine Chemical compound CN1C=CC(NC=2C(=CC(=CC=2)C(F)(F)F)N)=N1 JLAAUZHMAFBKAW-UHFFFAOYSA-N 0.000 description 2
- LKEOXLKJHPPOPZ-UHFFFAOYSA-N 3-(2,4-dinitroanilino)-1-methylpyrazole-4-carbonitrile Chemical compound CN1C=C(C#N)C(NC=2C(=CC(=CC=2)[N+]([O-])=O)[N+]([O-])=O)=N1 LKEOXLKJHPPOPZ-UHFFFAOYSA-N 0.000 description 2
- BVPIVWHLXCOLBQ-UHFFFAOYSA-N 3-(2-amino-4-nitroanilino)-1-methylpyrazole-4-carbonitrile Chemical compound CN1C=C(C#N)C(NC=2C(=CC(=CC=2)[N+]([O-])=O)N)=N1 BVPIVWHLXCOLBQ-UHFFFAOYSA-N 0.000 description 2
- XDQHZVOYUQKDCM-UHFFFAOYSA-N 3-(4-chloro-2-nitroanilino)-1-methylpyrazole-4-carbonitrile Chemical compound CN1C=C(C#N)C(NC=2C(=CC(Cl)=CC=2)[N+]([O-])=O)=N1 XDQHZVOYUQKDCM-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- ZZLCFHIKESPLTH-UHFFFAOYSA-N 4-Methylbiphenyl Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- RAENQYIFRBWIFU-UHFFFAOYSA-N 7-chloro-2-methyl-1,5-dihydropyrazolo[4,3-c][1,5]benzodiazepin-4-one Chemical compound N1C(=O)C2=CN(C)NC2=NC2=CC=C(Cl)C=C21 RAENQYIFRBWIFU-UHFFFAOYSA-N 0.000 description 2
- SYRNVSLFYCHAJQ-UHFFFAOYSA-N 7-fluoro-2-methyl-1,5-dihydropyrazolo[4,3-c][1,5]benzodiazepin-4-one Chemical compound N1C(=O)C2=CN(C)NC2=NC2=CC=C(F)C=C21 SYRNVSLFYCHAJQ-UHFFFAOYSA-N 0.000 description 2
- MYODITQJTYGHII-UHFFFAOYSA-N 7-fluoro-2-methyl-4-(4-methylpiperazin-1-yl)-1h-pyrazolo[4,3-c][1,5]benzodiazepine Chemical compound C1CN(C)CCN1C1=NC2=CC(F)=CC=C2NC2=NN(C)C=C12 MYODITQJTYGHII-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 229960001653 citalopram Drugs 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000011928 denatured alcohol Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 150000002463 imidates Chemical class 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 2
- 229920001021 polysulfide Polymers 0.000 description 2
- 239000005077 polysulfide Substances 0.000 description 2
- 150000008117 polysulfides Polymers 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- CWXOAQXKPAENDI-UHFFFAOYSA-N sodium methylsulfinylmethylide Chemical compound [Na+].CS([CH2-])=O CWXOAQXKPAENDI-UHFFFAOYSA-N 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000001119 stannous chloride Substances 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 150000003556 thioamides Chemical class 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- RZKKOBGFCAHLCZ-UHFFFAOYSA-N 1,4-dichloro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC=C1Cl RZKKOBGFCAHLCZ-UHFFFAOYSA-N 0.000 description 1
- PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 1
- TURQBFQJXWKTEM-UHFFFAOYSA-N 1-methyl-3-(2-nitroanilino)pyrazole-4-carbonitrile Chemical compound CN1C=C(C#N)C(NC=2C(=CC=CC=2)[N+]([O-])=O)=N1 TURQBFQJXWKTEM-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- PCYWMDGJYQAMCR-UHFFFAOYSA-N 1h-pyrrole-3-carbonitrile Chemical compound N#CC=1C=CNC=1 PCYWMDGJYQAMCR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- ZAXZHLVISULUAQ-UHFFFAOYSA-N 2-methyl-7-(trifluoromethyl)-1h-pyrazolo[3,4-b][1,5]benzodiazepin-4-amine Chemical compound N1=C(N)C2=CN(C)NC2=NC2=CC=C(C(F)(F)F)C=C21 ZAXZHLVISULUAQ-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- PIHLZHHNJOOWAB-UHFFFAOYSA-N 3-(4-fluoro-2-nitroanilino)-1-methylpyrazole-4-carboxylic acid Chemical compound FC1=CC(=C(NC2=NN(C=C2C(=O)O)C)C=C1)[N+](=O)[O-] PIHLZHHNJOOWAB-UHFFFAOYSA-N 0.000 description 1
- FBQOIRKIQMQJNS-UHFFFAOYSA-N 3-amino-1-methylpyrazole-4-carbonitrile Chemical compound CN1C=C(C#N)C(N)=N1 FBQOIRKIQMQJNS-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UQXLCQQSDUCPFW-UHFFFAOYSA-N 4-(4-benzylpiperazin-1-yl)-7-fluoro-2-methyl-1h-pyrazolo[4,3-c][1,5]benzodiazepine Chemical compound N=1N(C)C=C2C=1NC1=CC=C(F)C=C1N=C2N(CC1)CCN1CC1=CC=CC=C1 UQXLCQQSDUCPFW-UHFFFAOYSA-N 0.000 description 1
- ZEBMXWFZKAPFND-UHFFFAOYSA-N 4-[4-(cyclopropylmethyl)piperazin-1-yl]-7-fluoro-2-methyl-1h-pyrazolo[4,3-c][1,5]benzodiazepine Chemical compound N=1N(C)C=C2C=1NC1=CC=C(F)C=C1N=C2N(CC1)CCN1CC1CC1 ZEBMXWFZKAPFND-UHFFFAOYSA-N 0.000 description 1
- KCYVMBIUIPNYBO-UHFFFAOYSA-N 6-chloro-2-methyl-1h-pyrazolo[3,4-b][1,5]benzodiazepin-4-amine Chemical compound N1=C(N)C2=CN(C)NC2=NC2=CC=CC(Cl)=C21 KCYVMBIUIPNYBO-UHFFFAOYSA-N 0.000 description 1
- ZZNUDRJWRCLBTR-UHFFFAOYSA-N 7-bromo-2-methyl-1h-pyrazolo[3,4-b][1,5]benzodiazepin-4-amine Chemical compound N1=C(N)C2=CN(C)NC2=NC2=CC=C(Br)C=C21 ZZNUDRJWRCLBTR-UHFFFAOYSA-N 0.000 description 1
- NJZLEOQFKQUXKC-UHFFFAOYSA-N 7-chloro-2-(2-methylpropyl)-1h-pyrazolo[3,4-b][1,5]benzodiazepin-4-amine Chemical compound N1=C(N)C2=CN(CC(C)C)NC2=NC2=CC=C(Cl)C=C21 NJZLEOQFKQUXKC-UHFFFAOYSA-N 0.000 description 1
- KTOSFDGDKJOYRM-UHFFFAOYSA-N 7-chloro-2-ethyl-1h-pyrazolo[3,4-b][1,5]benzodiazepin-4-amine Chemical compound N1=C(N)C2=CN(CC)NC2=NC2=CC=C(Cl)C=C21 KTOSFDGDKJOYRM-UHFFFAOYSA-N 0.000 description 1
- WTJWTVFJDYRIKE-UHFFFAOYSA-N 7-chloro-2-methyl-1,5-dihydropyrazolo[4,3-c][1,5]benzodiazepine-4-thione Chemical compound N1C(=S)C2=CN(C)NC2=NC2=CC=C(Cl)C=C21 WTJWTVFJDYRIKE-UHFFFAOYSA-N 0.000 description 1
- XGECVIALSVGJCT-UHFFFAOYSA-N 7-chloro-2-methyl-1h-pyrazolo[3,4-b][1,5]benzodiazepin-4-amine Chemical compound N1C2=CC=C(Cl)C=C2N=C(N)C2=CN(C)N=C12 XGECVIALSVGJCT-UHFFFAOYSA-N 0.000 description 1
- JEORHAVBXBAKHX-UHFFFAOYSA-N 7-fluoro-2-methyl-1h-pyrazolo[3,4-b][1,5]benzodiazepin-4-amine Chemical compound N1=C(N)C2=CN(C)NC2=NC2=CC=C(F)C=C21 JEORHAVBXBAKHX-UHFFFAOYSA-N 0.000 description 1
- ODDAGPPBKZRYEU-UHFFFAOYSA-N 7-fluoro-2-methyl-4-(4-methyl-4-oxidopiperazin-4-ium-1-yl)-1h-pyrazolo[4,3-c][1,5]benzodiazepine Chemical compound N=1N(C)C=C2C=1NC1=CC=C(F)C=C1N=C2N1CC[N+](C)([O-])CC1 ODDAGPPBKZRYEU-UHFFFAOYSA-N 0.000 description 1
- OUUAJIUTRKTKJF-UHFFFAOYSA-N 7-fluoro-4-(4-methylpiperazin-1-yl)-2-propan-2-yl-1h-pyrazolo[4,3-c][1,5]benzodiazepine Chemical compound N=1N(C(C)C)C=C2C=1NC1=CC=C(F)C=C1N=C2N1CCN(C)CC1 OUUAJIUTRKTKJF-UHFFFAOYSA-N 0.000 description 1
- RQHXFSWHDAJVFR-UHFFFAOYSA-N 7-fluoro-4-(4-methylpiperazin-1-yl)-2-propyl-1h-pyrazolo[4,3-c][1,5]benzodiazepine Chemical compound N=1N(CCC)C=C2C=1NC1=CC=C(F)C=C1N=C2N1CCN(C)CC1 RQHXFSWHDAJVFR-UHFFFAOYSA-N 0.000 description 1
- HWNUNCPANIFMKE-UHFFFAOYSA-N 7-iodo-2-methyl-1h-pyrazolo[3,4-b][1,5]benzodiazepin-4-amine Chemical compound N1=C(N)C2=CN(C)NC2=NC2=CC=C(I)C=C21 HWNUNCPANIFMKE-UHFFFAOYSA-N 0.000 description 1
- AWTFPRSUYNRMKT-UHFFFAOYSA-N 7-iodo-2-methyl-4-(4-methylpiperazin-1-yl)-1h-pyrazolo[4,3-c][1,5]benzodiazepine Chemical compound C1CN(C)CCN1C1=NC2=CC(I)=CC=C2NC2=NN(C)C=C12 AWTFPRSUYNRMKT-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WHYKEEFBRCGTQC-UHFFFAOYSA-N 8-chloro-2-methyl-1h-pyrazolo[3,4-b][1,5]benzodiazepin-4-amine Chemical compound N1=C(N)C2=CN(C)NC2=NC2=CC(Cl)=CC=C21 WHYKEEFBRCGTQC-UHFFFAOYSA-N 0.000 description 1
- 241001502050 Acis Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- UEOQUHDCODAQFV-UHFFFAOYSA-N CCC1=CN(C)N=C1NC(C=C(C(F)=C1)F)=C1N Chemical compound CCC1=CN(C)N=C1NC(C=C(C(F)=C1)F)=C1N UEOQUHDCODAQFV-UHFFFAOYSA-N 0.000 description 1
- 208000009132 Catalepsy Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CDUSWRQFFJEBJU-UHFFFAOYSA-N N-(4-fluoro-2-nitrophenyl)-1-methylpyrazol-3-amine Chemical compound FC1=CC(=C(NC2=NN(C=C2)C)C=C1)[N+](=O)[O-] CDUSWRQFFJEBJU-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- AQLLBJAXUCIJSR-UHFFFAOYSA-N OC(=O)C[Na] Chemical compound OC(=O)C[Na] AQLLBJAXUCIJSR-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- MKYSOJQAHYTQQF-UHFFFAOYSA-N [3-[2-amino-4-(trifluoromethyl)anilino]-1-methylpyrazol-4-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CN(C)N=C1NC1=CC=C(C(F)(F)F)C=C1N MKYSOJQAHYTQQF-UHFFFAOYSA-N 0.000 description 1
- VFMGDDVBHNXWDY-UHFFFAOYSA-N [Cl].C(CC(O)(C(=O)O)CC(=O)O)(=O)O Chemical compound [Cl].C(CC(O)(C(=O)O)CC(=O)O)(=O)O VFMGDDVBHNXWDY-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- KDFQYGBJUYYWDJ-UHFFFAOYSA-N azane;sodium Chemical compound N.[Na] KDFQYGBJUYYWDJ-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- JSYGRUBHOCKMGQ-UHFFFAOYSA-N dichloramine Chemical compound ClNCl JSYGRUBHOCKMGQ-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- MCPLVIGCWWTHFH-UHFFFAOYSA-M disodium;4-[4-[[4-(4-sulfoanilino)phenyl]-[4-(4-sulfonatophenyl)azaniumylidenecyclohexa-2,5-dien-1-ylidene]methyl]anilino]benzenesulfonate Chemical compound [Na+].[Na+].C1=CC(S(=O)(=O)O)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[NH+]C=2C=CC(=CC=2)S([O-])(=O)=O)C=2C=CC(NC=3C=CC(=CC=3)S([O-])(=O)=O)=CC=2)C=C1 MCPLVIGCWWTHFH-UHFFFAOYSA-M 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940005482 dopamine injection Drugs 0.000 description 1
- 238000007336 electrophilic substitution reaction Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- YPGCDLACNYSDNW-UHFFFAOYSA-N ethyl 1-methyl-3-[2-nitro-4-(trifluoromethyl)anilino]pyrazole-4-carboxylate Chemical compound CCOC(=O)C1=CN(C)N=C1NC1=CC=C(C(F)(F)F)C=C1[N+]([O-])=O YPGCDLACNYSDNW-UHFFFAOYSA-N 0.000 description 1
- KACZQOKEFKFNDB-UHFFFAOYSA-N ethyl 1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1 KACZQOKEFKFNDB-UHFFFAOYSA-N 0.000 description 1
- CSENGGMJHCGVSP-UHFFFAOYSA-N ethyl 3-(2-amino-4-fluoroanilino)-1,5-dimethylpyrazole-4-carboxylate Chemical compound CCOC(=O)C1=C(C)N(C)N=C1NC1=CC=C(F)C=C1N CSENGGMJHCGVSP-UHFFFAOYSA-N 0.000 description 1
- NZRQVJYFDUESPP-UHFFFAOYSA-N ethyl 3-(2-amino-4-fluoroanilino)-1-ethylpyrazole-4-carboxylate Chemical compound CCOC(=O)C1=CN(CC)N=C1NC1=CC=C(F)C=C1N NZRQVJYFDUESPP-UHFFFAOYSA-N 0.000 description 1
- QFANGVVMUQUUAU-UHFFFAOYSA-N ethyl 3-(2-amino-4-fluoroanilino)-1-methylpyrazole-4-carboxylate Chemical compound CCOC(=O)C1=CN(C)N=C1NC1=CC=C(F)C=C1N QFANGVVMUQUUAU-UHFFFAOYSA-N 0.000 description 1
- UWHJSAGELWAJJP-UHFFFAOYSA-N ethyl 3-(2-amino-5-fluoroanilino)-1-methylpyrazole-4-carboxylate Chemical compound CCOC(=O)C1=CN(C)N=C1NC1=CC(F)=CC=C1N UWHJSAGELWAJJP-UHFFFAOYSA-N 0.000 description 1
- YKOZTQDEOZSPCY-UHFFFAOYSA-N ethyl 3-(2-aminoanilino)-1-methylpyrazole-4-carboxylate Chemical compound CCOC(=O)C1=CN(C)N=C1NC1=CC=CC=C1N YKOZTQDEOZSPCY-UHFFFAOYSA-N 0.000 description 1
- LDAZMTVMORAPMJ-UHFFFAOYSA-N ethyl 3-amino-1,5-dimethylpyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C(N)=NN(C)C=1C LDAZMTVMORAPMJ-UHFFFAOYSA-N 0.000 description 1
- HHYVTIKYZUMDIL-UHFFFAOYSA-N ethyl 5-methyl-1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1C HHYVTIKYZUMDIL-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229910052735 hafnium Inorganic materials 0.000 description 1
- VBJZVLUMGGDVMO-UHFFFAOYSA-N hafnium atom Chemical compound [Hf] VBJZVLUMGGDVMO-UHFFFAOYSA-N 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- XKBGEWXEAPTVCK-UHFFFAOYSA-M methyltrioctylammonium chloride Chemical compound [Cl-].CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC XKBGEWXEAPTVCK-UHFFFAOYSA-M 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- ZIJBFGQFPYFAFA-UHFFFAOYSA-N n-(4-iodo-2-nitrophenyl)-1-methylpyrazol-3-amine Chemical compound CN1C=CC(NC=2C(=CC(I)=CC=2)[N+]([O-])=O)=N1 ZIJBFGQFPYFAFA-UHFFFAOYSA-N 0.000 description 1
- AKCCIPCPEVWZEO-UHFFFAOYSA-N n-(5-fluoro-2-nitrophenyl)-1-methylpyrazol-3-amine Chemical compound CN1C=CC(NC=2C(=CC=C(F)C=2)[N+]([O-])=O)=N1 AKCCIPCPEVWZEO-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- RPESBQCJGHJMTK-UHFFFAOYSA-I pentachlorovanadium Chemical class [Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[V+5] RPESBQCJGHJMTK-UHFFFAOYSA-I 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- GLBQVJGBPFPMMV-UHFFFAOYSA-N sulfilimine Chemical class S=N GLBQVJGBPFPMMV-UHFFFAOYSA-N 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB7935846 | 1979-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH646700A5 true CH646700A5 (fr) | 1984-12-14 |
Family
ID=10508540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH763980A CH646700A5 (fr) | 1979-10-16 | 1980-10-14 | Composes de benzodiazepine et produits pharmaceutiques les contenant. |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US4404137A (en:Method) |
| EP (1) | EP0027390B1 (en:Method) |
| JP (1) | JPS5663987A (en:Method) |
| KR (2) | KR850000471B1 (en:Method) |
| AR (2) | AR228041A1 (en:Method) |
| AT (1) | AT373889B (en:Method) |
| AU (1) | AU538500B2 (en:Method) |
| BE (1) | BE885729A (en:Method) |
| BG (2) | BG34907A3 (en:Method) |
| CA (1) | CA1159056A (en:Method) |
| CH (1) | CH646700A5 (en:Method) |
| CS (1) | CS244409B2 (en:Method) |
| DD (1) | DD153692A5 (en:Method) |
| DE (1) | DE3068706D1 (en:Method) |
| DK (1) | DK437480A (en:Method) |
| ES (1) | ES8106905A1 (en:Method) |
| FI (1) | FI67550C (en:Method) |
| FR (1) | FR2467851A1 (en:Method) |
| GB (1) | GB8327127D0 (en:Method) |
| GR (1) | GR70720B (en:Method) |
| HU (1) | HU182213B (en:Method) |
| IE (1) | IE50358B1 (en:Method) |
| IL (1) | IL61264A (en:Method) |
| IT (1) | IT1143047B (en:Method) |
| LU (1) | LU82853A1 (en:Method) |
| MX (1) | MX6233E (en:Method) |
| NZ (1) | NZ195248A (en:Method) |
| PH (2) | PH16288A (en:Method) |
| PL (2) | PL135044B1 (en:Method) |
| PT (1) | PT71913B (en:Method) |
| RO (2) | RO85822B (en:Method) |
| YU (1) | YU261580A (en:Method) |
| ZA (1) | ZA806342B (en:Method) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4404137A (en) * | 1979-10-16 | 1983-09-13 | Lilly Industries Limited | Pyrazolo [3,4-b][1,5]benzodiazepine compounds |
| US4431589A (en) * | 1980-12-11 | 1984-02-14 | Lilly House | Benzodiazepine compounds and their use as pharmaceuticals |
| US4596799A (en) * | 1985-01-29 | 1986-06-24 | Ciba-Geigy Corporation | 9H-pyrrolo[2,1-c]-1,2,4-triazolo[4,3-a][1,4]benzodiazepines |
| TW219896B (en:Method) * | 1988-07-07 | 1994-02-01 | Duphar Int Res | |
| GB8819059D0 (en) * | 1988-08-11 | 1988-09-14 | Lilly Industries Ltd | Benzodiazepine compounds & their use as pharmaceuticals |
| US5631250A (en) * | 1995-03-24 | 1997-05-20 | Eli Lilly And Company | Process and solvate of 2-methyl-thieno-benzodiazepine |
| US5637584A (en) * | 1995-03-24 | 1997-06-10 | Eli Lilly And Company | Solvate of olanzapine |
| EP1994932A1 (en) * | 2003-01-23 | 2008-11-26 | Arcadia Pharmaceuticals Inc. | Use of N-desmethylclozapine to treat human psychosis |
| US20050085463A1 (en) * | 2003-01-23 | 2005-04-21 | Weiner David M. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| US20050250767A1 (en) * | 2003-01-23 | 2005-11-10 | Weiner David M | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| ES2324713T3 (es) * | 2003-12-22 | 2009-08-13 | Acadia Pharmaceuticals Inc. | Analogos de diaril(a,d)ciclohepteno amino-sustituidos como agonistas muscarinicos y metodos de tratamiento de trastornos neuropsiquiatricos. |
| MXPA06011320A (es) * | 2004-04-01 | 2007-03-21 | Acadia Pharm Inc | Metodo de sintesis y aislamiento de n-desmetilclozapina solida y sus formas cristalinas. |
| WO2007053618A1 (en) * | 2005-10-31 | 2007-05-10 | Acadia Pharmaceuticals Inc. | Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| JP5438482B2 (ja) * | 2009-12-03 | 2014-03-12 | Ｊｕｋｉ株式会社 | ミシン、ミシンの縫製データ編集装置及びミシンの縫製データ編集プログラム |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3450694A (en) * | 1966-02-23 | 1969-06-17 | Abbott Lab | Substituted benzoxazepines and benzothiazepines |
| US3758479A (en) * | 1967-03-22 | 1973-09-11 | Sandoz Ag | Nitro and sulphamoyl substituted dibenzodiazepines |
| DE1795183B1 (de) * | 1968-08-20 | 1972-07-20 | Thomae Gmbh Dr K | 5,11-Dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-on-derivate und Arzneimittel |
| CA918659A (en) * | 1969-07-31 | 1973-01-09 | Yoshitomi Pharmaceutical Industries | 11-(4-substituted-1-piperazinyl)-dibenzo (b,f) (1,4) thiazepines |
| US4115568A (en) * | 1974-11-26 | 1978-09-19 | Lilly Industries Limited | Thieno[3,2-b]-[1,5]benzodiazepines |
| US4172831A (en) * | 1974-11-26 | 1979-10-30 | Lilly Industries Limited | Thieno-benzodiazepines |
| US3953430A (en) * | 1975-02-24 | 1976-04-27 | American Cyanamid Company | Substituted benzodiazepin-10-ones and method of use |
| US3951981A (en) * | 1975-02-24 | 1976-04-20 | American Cyanamid Company | Substituted benzodiazepines and method of use |
| DE2707270A1 (de) * | 1977-02-19 | 1978-08-24 | Hoechst Ag | Pyrazolo-diazepine und verfahren zu ihrer herstellung |
| DE2707269A1 (de) * | 1977-02-19 | 1978-08-24 | Hoechst Ag | Heterocyclische stickstoffverbindungen und verfahren zu ihrer herstellung |
| US4097597A (en) * | 1977-02-23 | 1978-06-27 | Abbott Laboratories | Dibenzo b,e! 1,4!diazepines |
| IT7851496A0 (it) * | 1977-10-31 | 1978-10-13 | Sandoz Ag | Menti pirazinobenzossazepine loro preparazione e loro impiego quali medica |
| CH643263A5 (de) * | 1979-05-11 | 1984-05-30 | Sandoz Ag | Benzodiazepine, ihre herstellung und verwendung. |
| DE3029281A1 (de) * | 1979-08-03 | 1981-02-19 | Byk Gulden Lomberg Chem Fab | Substituierte tetraazatricyclen, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende arzneimittel |
| US4404137A (en) * | 1979-10-16 | 1983-09-13 | Lilly Industries Limited | Pyrazolo [3,4-b][1,5]benzodiazepine compounds |
-
1980
- 1980-10-02 US US06/193,200 patent/US4404137A/en not_active Expired - Lifetime
- 1980-10-11 GR GR63138A patent/GR70720B/el unknown
- 1980-10-13 RO RO108967A patent/RO85822B/ro unknown
- 1980-10-13 NZ NZ195248A patent/NZ195248A/xx unknown
- 1980-10-13 CS CS806938A patent/CS244409B2/cs unknown
- 1980-10-13 FR FR8021823A patent/FR2467851A1/fr active Granted
- 1980-10-13 YU YU02615/80A patent/YU261580A/xx unknown
- 1980-10-13 MX MX809093U patent/MX6233E/es unknown
- 1980-10-13 PH PH24717A patent/PH16288A/en unknown
- 1980-10-13 IL IL61264A patent/IL61264A/xx unknown
- 1980-10-13 RO RO102349A patent/RO81351B/ro unknown
- 1980-10-14 AU AU63252/80A patent/AU538500B2/en not_active Ceased
- 1980-10-14 PT PT71913A patent/PT71913B/pt unknown
- 1980-10-14 CA CA000362328A patent/CA1159056A/en not_active Expired
- 1980-10-14 AT AT0510180A patent/AT373889B/de not_active IP Right Cessation
- 1980-10-14 CH CH763980A patent/CH646700A5/fr not_active IP Right Cessation
- 1980-10-14 IT IT49899/80A patent/IT1143047B/it active
- 1980-10-15 FI FI803253A patent/FI67550C/fi not_active IP Right Cessation
- 1980-10-15 EP EP80303649A patent/EP0027390B1/en not_active Expired
- 1980-10-15 DE DE8080303649T patent/DE3068706D1/de not_active Expired
- 1980-10-15 BG BG049366A patent/BG34907A3/xx unknown
- 1980-10-15 ES ES495948A patent/ES8106905A1/es not_active Expired
- 1980-10-15 JP JP14423180A patent/JPS5663987A/ja active Pending
- 1980-10-15 PL PL1980231270A patent/PL135044B1/pl unknown
- 1980-10-15 DK DK437480A patent/DK437480A/da not_active Application Discontinuation
- 1980-10-15 KR KR1019800003960A patent/KR850000471B1/ko not_active Expired
- 1980-10-15 PL PL1980227306A patent/PL126824B1/pl unknown
- 1980-10-15 IE IE2135/80A patent/IE50358B1/en unknown
- 1980-10-15 DD DD80224618A patent/DD153692A5/de unknown
- 1980-10-15 BE BE6/47291A patent/BE885729A/fr not_active IP Right Cessation
- 1980-10-15 LU LU82853A patent/LU82853A1/fr unknown
- 1980-10-15 BG BG057344A patent/BG35042A3/xx unknown
- 1980-10-15 HU HU802502A patent/HU182213B/hu not_active IP Right Cessation
- 1980-10-15 ZA ZA00806342A patent/ZA806342B/xx unknown
- 1980-10-16 AR AR282893A patent/AR228041A1/es active
-
1982
- 1982-07-21 AR AR290034A patent/AR228101A1/es active
- 1982-07-28 PH PH27643A patent/PH17759A/en unknown
- 1982-09-29 US US06/426,580 patent/US4486591A/en not_active Expired - Fee Related
-
1983
- 1983-10-11 GB GB838327127A patent/GB8327127D0/en active Pending
-
1984
- 1984-07-24 KR KR1019840004388A patent/KR850000472B1/ko not_active Expired
- 1984-08-06 US US06/638,181 patent/US4542131A/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0112776B1 (fr) | Médicaments à base de dérivés de naphtalène- ou azanaphtalènecarboxamide, nouveaux dérivés de naphtalène- ou azanaphtalènecarboxamide et procédés pour leur préparation | |
| CH646700A5 (fr) | Composes de benzodiazepine et produits pharmaceutiques les contenant. | |
| FR2628108A1 (fr) | Derives de piperazine et leurs sels, leurs procedes de fabrication et compositions pharmaceutiques les comprenant comme ingredients actifs | |
| EP0003383A2 (fr) | Dérivés de 4-amino-3-sulfonamido-pyridine | |
| FR2665441A1 (fr) | Derives de la n-sulfonyl indoline, leur preparation, les compositions pharmaceutiques en contenant. | |
| FR2561647A1 (fr) | Derives de 1-(hydroxymethyl)-1,6,7,11b-tetrahydro-2h,4h-(1,3)-oxazino- ou -thiazino(4,3,a)isoquinoleine, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| CH646967A5 (fr) | Composes de pyranone et compositions pharmaceutiques les comprenant. | |
| EP2185561B1 (fr) | Dérivés de 1,2,3,4-tétrahydropyrrolo(1,2-a)pyrazine-6-carboxamides et de 2,3,4,5-tétrahydropyrrolo(1,2-a)-diazépine-7-carboxamides, leur préparation et leur application en thérapeutique | |
| CA2055326A1 (fr) | Derives de la n-benzoyl proline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| FR2944524A1 (fr) | Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament | |
| CH647233A5 (fr) | Composes de methylene-3-azetidine utiles comme medicaments et compositions therapeutiques les contenant. | |
| US4492699A (en) | Triazolobenzodiazepine derivatives | |
| JP2779219B2 (ja) | ベンゾジアゼピン化合物及び該化合物を含有する医薬組成物 | |
| EP0573318A1 (fr) | Nouveaux dérivés de phényle carboxamide isoxazoles et leurs sels, leur procédé de préparation et les nouveaux intermédiaires de ce procédé, leur application comme médicaments et les compositions pharmaceutiques les renfermant | |
| FR2530632A1 (fr) | Nouveaux derives substitues du 2,5-diamino 1,4-diazole, leurs procedes de preparation et les compositions pharmaceutiques en renfermant | |
| EP0156734A2 (fr) | Triazolo[4,3-b]pyridazines, procédé pour leur préparation et compositions pharmaceutiques les contenant | |
| CH645370A5 (fr) | Composes de pyranone et compositions pharmaceutiques les contenant. | |
| CH659469A5 (fr) | Derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation et les medicaments et compositions les renfermant. | |
| EP0384843B1 (fr) | Dérivés de la 1-arylsulfonyl 2-pipéridinone, leur procédé et les intermédiaires de préparation, leur application comme médicaments et les compositions les renfermant | |
| EP0196943B1 (fr) | Nouveaux dérivés 8-thiotétrahydroquinoléines et leurs sels | |
| EP0305298B1 (fr) | Nouvelles imidazo benzodiazépines et leurs sels d'addition avec les acides, leur procédé et les intermédiaires de préparation, leur application comme médicaments et les compositions les renfermant | |
| EP0362006A1 (fr) | Dérivés de quinoléine, leurs procédés de préparation et les médicaments les contenant | |
| EP0161143A1 (fr) | Nouvelles 1,2,4-thiadiazines et leurs sels, leur procédé et leurs intermédiaires de préparation, leur application à titre de médicaments et les compositions les renfermant | |
| EP0538100A1 (fr) | Nouveaux dérivés de l'acide fluoro quinoléine carboxylique-3 et leur préparation | |
| EP1659112A1 (fr) | Dérivés d'arylpipérazine comme ligands sélectifs du récepteur D3 de la dopamine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |